Tarsier Pharma’s stalled IPO process underpins the 96.6% market-implied probability of no listing before September 2026. Multiple F-1/A amendments through mid-July 2026 followed the initial April filing and May–July term-sheet updates for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet no pricing date or listing has materialized. As a clinical-stage Israeli biotech with zero product revenue and a Phase 3 program still advancing, the micro-cap deal faces typical delays or withdrawals seen in similar offerings. The compressed window to the August 31 resolution leaves scant room for completion. A sudden institutional anchor or regulatory green light could still shift odds, though historical precedent favors further postponement.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयासितंबर 2026 से पहले कोई आईपीओ नहीं 96.7%
$300M-$350M <1%
$350M-$400M <1%
$400M-$450M <1%
$17,975 वॉल्यूम
$17,975 वॉल्यूम
31 अग, 2026
<$250M
<1%
$250M-$300M
<1%
$300M-$350M
<1%
$350M-$400M
<1%
$400M-$450M
<1%
>$450M
<1%
सितंबर 2026 से पहले कोई आईपीओ नहीं
97%
सितंबर 2026 से पहले कोई आईपीओ नहीं 96.7%
$300M-$350M <1%
$350M-$400M <1%
$400M-$450M <1%
$17,975 वॉल्यूम
$17,975 वॉल्यूम
31 अग, 2026
<$250M
$1,152 वॉल्यूम
<1%
$250M-$300M
$1,113 वॉल्यूम
<1%
$300M-$350M
$1,642 वॉल्यूम
<1%
$350M-$400M
$837 वॉल्यूम
<1%
$400M-$450M
$629 वॉल्यूम
<1%
>$450M
$1,068 वॉल्यूम
<1%
सितंबर 2026 से पहले कोई आईपीओ नहीं
$11,534 वॉल्यूम
97%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma’s stalled IPO process underpins the 96.6% market-implied probability of no listing before September 2026. Multiple F-1/A amendments through mid-July 2026 followed the initial April filing and May–July term-sheet updates for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet no pricing date or listing has materialized. As a clinical-stage Israeli biotech with zero product revenue and a Phase 3 program still advancing, the micro-cap deal faces typical delays or withdrawals seen in similar offerings. The compressed window to the August 31 resolution leaves scant room for completion. A sudden institutional anchor or regulatory green light could still shift odds, though historical precedent favors further postponement.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
बाज़ार खुला: Jul 7, 2026, 9:12 AM ET
वॉल्यूम
$17,975समाप्ति तिथि
1 सित, 2026बाज़ार खुला
Jul 7, 2026, 9:12 AM ETरिज़ॉल्वर
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma’s stalled IPO process underpins the 96.6% market-implied probability of no listing before September 2026. Multiple F-1/A amendments through mid-July 2026 followed the initial April filing and May–July term-sheet updates for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet no pricing date or listing has materialized. As a clinical-stage Israeli biotech with zero product revenue and a Phase 3 program still advancing, the micro-cap deal faces typical delays or withdrawals seen in similar offerings. The compressed window to the August 31 resolution leaves scant room for completion. A sudden institutional anchor or regulatory green light could still shift odds, though historical precedent favors further postponement.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
वॉल्यूम
$17,975समाप्ति तिथि
1 सित, 2026बाज़ार खुला
Jul 7, 2026, 9:12 AM ETरिज़ॉल्वर
0x69c47De9D...Tarsier Pharma’s stalled IPO process underpins the 96.6% market-implied probability of no listing before September 2026. Multiple F-1/A amendments through mid-July 2026 followed the initial April filing and May–July term-sheet updates for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet no pricing date or listing has materialized. As a clinical-stage Israeli biotech with zero product revenue and a Phase 3 program still advancing, the micro-cap deal faces typical delays or withdrawals seen in similar offerings. The compressed window to the August 31 resolution leaves scant room for completion. A sudden institutional anchor or regulatory green light could still shift odds, though historical precedent favors further postponement.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न